Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.9K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.9K
RNA Splicing01:32

RNA Splicing

61.9K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.9K
T Cell Types and Functions01:24

T Cell Types and Functions

3.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

2.2K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K
Alternative RNA Splicing02:18

Alternative RNA Splicing

27.6K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
27.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same author

Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.

EULAR rheumatology open·2026
Same author

Head-To-Head Intra Individual Comparison of Three Therapeutic Apheresis Modalities in Chronic Auto-Immune Neuropathy: A Real-World Experience.

Journal of clinical apheresis·2026
Same author

Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.

Blood advances·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.

Haematologica·2026

Related Experiment Video

Updated: Apr 20, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Charline Vauchy1, Clementine Gamonet, Christophe Ferrand

  • 1INSERM UMR1098, F25020 Besançon cedex, France; Université de Franche-Comté, F25020 Besançon cedex, France; EFS Bourgogne Franche-Comté, F25020 Besançon cedex, France.

International Journal of Cancer
|December 3, 2014
PubMed
Summary

Cancer splice variants like D393-CD20 create neo-antigens for targeted immunotherapy. This study found D393-CD20 specific T cells in lymphoma patients, suggesting its potential for treating B cell malignancies.

Keywords:
B-cell lymphomaCD20 antigenCD4 T cellsimmunotherapysplicing

More Related Videos

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain
08:48

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

9.1K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain
08:48

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain

Published on: October 25, 2016

9.1K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer-specific splice variants are emerging targets for cancer immunotherapy due to neo-antigen generation.
  • CD20, a B cell marker, undergoes alternative splicing (D393-CD20), resulting in loss of membrane expression and potential for immune targeting.

Purpose of the Study:

  • To investigate the translation and immunogenicity of the D393-CD20 splice variant in B cell lymphomas.
  • To evaluate the potential of D393-CD20-derived epitopes for cancer immunotherapy.

Main Methods:

  • Detection of D393-CD20 translation in malignant B cells.
  • Identification and characterization of D393-CD20 specific CD4 T cell responses (IFN-γ production) in lymphoma patients.
  • Assessment of D393-CD20-specific CD4 Th1 clone recognition and killing of tumor cells.
  • Evaluation of D393-CD20 peptide-based vaccination in HLA-humanized transgenic mice.

Main Results:

  • D393-CD20 is translated in malignant B cells, and specific CD4 T cells are present in B-cell lymphoma patients.
  • D393-CD20-specific CD4 Th1 clones recognize and kill malignant B cell lines and autologous lymphoma cells.
  • Vaccination with D393-CD20 peptide elicits CD8 and CD4 T cell responses in mice, indicating presentation on HLA Class-I and -II.

Conclusions:

  • D393-CD20-derived epitopes are naturally processed and presented on tumor cells.
  • The D393-CD20 splice variant holds promise as a target for specific immunotherapy in B cell malignancies.